Key facts
- This page summarizes John F. Thero's Form 4 filing for Cyteir Therapeutics, Inc..
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 12 Feb 2024, 16:00.
John F. Thero - 08 Feb 2024 Form 4 Insider Report for Cyteir Therapeutics, Inc.
- Reporting relationship
- Director
- Issuer ticker
- N/A
- Reported as of
- 08 Feb 2024
- Net transaction value
- +$21,679
- SEC form
- 4
- Accepted by SEC
- 12 Feb 2024, 16:00:17 UTC
- Prior SEC filing
- 24 Feb 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/ David Gaiero, as attorney-in-fact for John F. Thero
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
John F. Thero filed Form 4 for Cyteir Therapeutics, Inc. on 12 Feb 2024.
Change
- Previous filing in this sequence was filed on 24 Feb 2023.
- Current net transaction value: +$21,679.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
CYT
transaction
Common Stock
Options Exercise
- Transaction value
- $21,679
- Shares
- +12,828
- Change %
- +128%
- Price
- $1.69
- Shares after
- 22,828
- Date
- 08 Feb 2024
- Ownership
- Direct
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
CYT
transaction
Derivative
Stock Option (Right to Buy)
Options Exercise
- Transaction value
- $0
- Shares
- -12,828
- Change %
- -100%
- Price
- $0.000000*
- Shares after
- 0
- Date
- 08 Feb 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 12,828
- Exercise price
- $1.69
* marks a reported price that did not pass the local price check.